Dr. Yu’s team is interested in assisted reproductive technologies (ART) and ovarian carcinogenesis. The main goals are to: 1) Develop non-invasive preimplantation and preconception genetic testing; 2) Understand the initiating events of ovarian cancer for early detection; and 3) Examine the impact of ART on the long-term health and future generations. They use animal and organoid model, and a combination of cellular & molecular biology, genomics, and molecular imaging methods in their studies.

Dr. Ruike Renee Zhao is an Assistant Professor of Mechanical Engineering at Stanford University, where she directs the Soft Intelligent Materials Laboratory. Dr. Zhao received her BS degree from Xi'an Jiaotong University in 2012, and her MS and PhD degrees from Brown University in 2014 and 2016, respectively. She was a postdoc associate at MIT during 2016-2018 prior to her appointment as an Assistant Professor in the Department of Mechanical and Aerospace Engineering at The Ohio State University from 2018 to 2021.

Dr. Juliet Knowles is Assistant Professor in Neurology at Stanford. Dr. Knowles is a physician-scientist who provides clinical care for children with epilepsy and leads a lab team conducting basic, translational and clinical research on pediatric epilepsy. She completed her M.D. and Ph.D. in Neurosciences at Stanford University, followed by residency training in Pediatrics and Child Neurology at Stanford, where she also served as Chief Resident. Following clinical fellowship training in Pediatric Epilepsy, Dr.

Dr. Laura Prolo is an Assistant Professor in the Department of Neurosurgery at Stanford University School of Medicine. After receiving her A.B. in Biology and Philosophy-Neuroscience-Psychology from Washington University in St. Louis, she completed her MD and PhD in Neuroscience from Stanford University. She remained at Stanford for Neurosurgery residency, then completed a fellowship in Pediatric Neurosurgery at University of Washington/Seattle Children’s Hospital.

Dr. Gen Shinozaki's research interests include investigation epigenetics mechanism of delirium pathophysiology, neuroinflammation and aging using human and mouse samples. Dr. Shinozaki's group aims to develop epigenetic biomarkers for delirium to predict, detect and monitor illness course, treatment response and patient outcomes. They are also working on a small point-of-care EEG device to detect delirium and predict patient outcome.

Dr. Neir Eshel (he/him/his) is a tenure-track Assistant Professor in the Department of Psychiatry & Behavioral Sciences at Stanford University School of Medicine. His clinical focus is the full-spectrum mental health care of sexual and gender minorities, with particular interest in depression, anxiety, and the complex effects of trauma in this population. He works in collaboration with other primary care and mental health providers at the new Stanford LGBTQ+ program.

Dr. Scott Owen's lab studies how neuromodulation can shape the activity of targeted cell types and circuits to guide behavior. Their goal is to understand how specialized physiology, connectivity, and cell-signaling support the diverse functions of individual neuronal cell types. How can a deeper understanding of these features guide future therapeutic interventions for neurological diseases including Autism, Obsessive-Compulsive Disorder, and Parkinson’s Disease?

A viable organ engineering pipeline requires the mass production of hundreds of billions of cells, tailorable and programmable cellular composition, and technologies to assemble these cells with perfusable vascular networks to support cell viability. Dr. Mark Skylar-Scott's lab is developing integrative technologies, including wetware, hardware, and software, to address cardiac tissue engineering at whole-organ scale.

Dr. Jesse Engreitz is an Assistant Professor in the Department of Genetics and the Children’s Heart Center Basic Sciences and Engineering (BASE) Initiative.

Dr. Boris Heifets's research group is dedicated to understanding and improving on powerful, rapid-acting therapies for psychiatric disease, such as ketamine, MDMA and psilocybin. They bridge basic science and clinical trials, connecting neuroscience, psychiatry and anesthesiology in pursuit of highly effective, safe treatment strategies scalable to the millions of patients who need them.